Phase III UNITY-CLL Trial Shows Promise for Umbralisib, Ublituximab Combo in CLL

The phase III UNITY-CLL trial evaluating the combination of umbralisib plus ublituximab met its primary endpoint at a prespecified interim analysis and will be stopped early for superior efficacy.

Source: CancerNetwork - May 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news